Detalles de la búsqueda
1.
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Clin Gastroenterol Hepatol
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38729389
2.
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
BMC Gastroenterol
; 24(1): 121, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539103
3.
Efficacy of Induction Therapy With Calcineurin Inhibitors in Combination With Ustekinumab for Acute Severe Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 21(5): 1354-1355.e2, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35307594
4.
Adalimumab in Biologic-naïve Patients With Crohn's Disease After Resolution of an Intra-abdominal Abscess: A Prospective Study From the GETAID.
Clin Gastroenterol Hepatol
; 21(13): 3365-3378.e5, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36731588
5.
Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial.
Clin Gastroenterol Hepatol
; 20(12): 2868-2875.e1, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35272029
6.
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
Clin Gastroenterol Hepatol
; 20(8): 1671-1686.e16, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33933376
7.
Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicentre, Prospective, Observational Cohort (REGAIN) Study from the GETAID.
Am J Gastroenterol
; 117(9): 1482-1490, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35973142
8.
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
Scand J Gastroenterol
; 57(12): 1454-1462, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35819361
9.
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
BMC Gastroenterol
; 22(1): 498, 2022 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36457080
10.
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
BMC Gastroenterol
; 22(1): 291, 2022 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35676620
11.
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study.
Dig Dis Sci
; 67(9): 4525-4532, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35246801
12.
Validation Study of a New Random-Access Chemiluminescence Immunoassay Analyzer i-TRACK10® to Monitor Infliximab and Adalimumab Serum trough Levels and Anti-Drug Antibodies.
Int J Mol Sci
; 23(17)2022 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36076966
13.
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501).
BMC Immunol
; 22(1): 81, 2021 12 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-34953484
14.
Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine.
Clin Gastroenterol Hepatol
; 19(6): 1180-1188.e4, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32777552
15.
No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
Dig Dis Sci
; 66(8): 2744-2749, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32936345
16.
Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease.
Dig Dis Sci
; 66(12): 4429-4435, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33387123
17.
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Gut
; 69(7): 1206-1212, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31980448
18.
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.
Clin Gastroenterol Hepatol
; 18(7): 1553-1560.e1, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31470175
19.
Infliximab levels and antibodies in IBD-related peripheral arthralgia.
Int J Colorectal Dis
; 35(6): 1141-1148, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32296932
20.
Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease.
J Pediatr Gastroenterol Nutr
; 70(3): 310-317, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31651668